Webinar Date/Time: Mon, Dec 4, 2023 11:00 AM EST
Hear from clinical development and site experts as they discuss takeaways from recent in-depth interviews with investigate sites, conducted by the Tufts Center for the Study of Drug Development,to understand the current challenges they are facing, potential solutions, and measures of success for productive sponsor/CRO relationships.
Events in recent years have strained investigative sites on unprecedented levels—from the sharp increase in studies to complex protocols, technology overload, and the explosion of data requirements.
Parexel recently partnered with The Tufts Center for the Study of Drug Development (CSDD) to conduct in-depth interviews of investigative sites to understand the current challenges they are facing, hear their thoughts on potential solutions, and consider measures of success for productive sponsor/CRO/site relationships.
This webinar brings together clinical development and site experts to discuss the sites’ feedback, including the biggest surprises, the greatest opportunities for improvement, and the steps that Parexel is taking to make a difference.
Key Learning Objectives
Vice President, Global Site Alliances,
Karen has 30 years’ experience in a clinical research organization (CRO) and Site Management Organization (SMO) in a variety of positions. With a special interest in site partnership, she has been involved in the development of Site Support Management tools with the goal to improve quality, transparency, and compliance across investigative sites since 2005. Karen’s current position within Parexel Launch Excellence Office as Vice President, Global Site Alliance provides the privileged opportunity to develop purposeful partnerships with sites globally. She brings extensive experience in a variety of therapeutic areas including cardiovascular, neuroscience and infectious diseases in phase II through phase IV clinical trials. Karen is also an active member and Chair of NREC Scotland.
Executive Director, Research Professor (PHCM),
Tufts Center for the Study of Drug Development
Ken Getz is the Executive Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine. He is an internationally recognized expert of pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage, and patient engagement. A well-known speaker at conferences, symposia, universities, investor meetings, and corporations, Ken has published extensively in peer-review journals, books, and in the trade press. He holds a number of board appointments in the private and public sectors. He received his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and his Bachelor’s degree from Brandeis University. Ken is also the chairman of CISCRP, a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise. Ken is the founder of CenterWatch, a leading publisher in the clinical trials industry and one of several businesses that he has sold.
Jeff Kingsley, DO, MBA, CPI, FACRP
Chief Development Officer,
Dr. Kingsley is Chief Development Officer and board member of Centricity Research, an integrated research organization with 36 integrated clinical research sites across the US and Canada. Centricity conducts phase I through IV research in nearly every medical specialty; inpatient and outpatient; pharmaceutical, biotechnology, and medical device. His mission is to create a new paradigm of research that allows brilliant minds to innovate faster and to deliver those new ideas the patients who need them. Centricity is focused aggressively on mergers and acquisitions and strives to lead the industry as the organization to join. Dr. Kingsley leads this effort.
Register Free: https://www.appliedclinicaltrialsonline.com/act/improved-site-experience